title: Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
abstract: Competition in the biological market offers a new set of opportunities and challenges within the healthcare industry. Biosimilars, like generic small-molecule drugs, can provide cost savings and increase patient access, while also promoting innovation. While large molecule manufacturers face many challenges unique to complex therapeutics, it is becoming clear that the commercialization of biosimilars shares many of the same hurdles as the generics market. The 14th Annual Business of Biosimilars Conference provided quality presentations from industry leaders regarding many commercial considerations for stakeholders interested in entering the biosimilars market. Opportunities to network with industry experts were offered, with over 120 attendees.
authors: Thomson Reuters, Portland, Maryland, USA. andrew.bourgoin@thomsonreuters.com.
authors: A
authors: A
authors: Bourgoin
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000191:economics*; D015195:Drug Design; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration; D016568:Drugs, Generic / Q000191:economics; D004465:Economic Competition; D006801:Humans; D007880:Legislation, Drug
chemical_list: D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic
keywords: Biologics; Biosimilar regulations; Biosimilars